Avacta to Present Pre-Clinical Data on AVA3996 at the American Association for Cancer Research Annual Meeting
Retrieved on:
Monday, March 27, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Clinical Trials, AACR, Fiona McLaughlin, Orange County Convention Center, Therapeutic index, American Association for Cancer Research, FAP, Neoplasm, Annual general meeting, Fibroblast activation protein, alpha, Peripheral neuropathy, Poster, Toxic encephalopathy, Tumor microenvironment, Proteasome inhibitor, Biology, Disease
The poster describes the data and pre-clinical rationale for the further development and disease positioning of the Company’s second pre|CISION™ candidate, AVA3996, a tumour microenvironment activated proteasome inhibitor.
Key Points:
- The poster describes the data and pre-clinical rationale for the further development and disease positioning of the Company’s second pre|CISION™ candidate, AVA3996, a tumour microenvironment activated proteasome inhibitor.
- AVA3996 utilises Avacta’s pre|CISION™ platform to improve the therapeutic index and therefore utility of proteasome inhibitors in tumours with high FAP levels, including both solid and haematological tumours.
- AVA3996 has the potential to deliver efficacious levels of the proteasome inhibitor warhead directly to the tumour microenvironment while reducing systemic exposure and hence associated toxicities, such as peripheral neuropathy.
- Attending the conference from Avacta will be Fiona McLaughlin – Chief Scientific Officer, Neil Bell – Chief Development Officer, David Jones – VP Biology and Francis Wilson – VP Chemistry.